Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of ...

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Europe

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 25 August 2026 · Fusion42 review

Arrowhead Pharmaceuticals will present pivotal Phase 3 clinical trial results for plozasiran, a treatment for severe hypertriglyceridemia, at the European Society of Cardiology Congress in Munich. The drug is already approved in multiple major markets and targets high triglyceride levels associated with acute pancreatitis and cardiovascular disease.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Cardiovascular drug developers should note that plozasiran's positive Phase 3 data and existing multi-market approvals open new routes for treatment and competitive positioning in severe hypertriglyceridemia care.

◆ Coverage

1 source · 24 Aug 2026

◆ Related on Wire

◆ Topics

Biotechplozasiranclinical-trialscardiovasculardrug-approvalhypertriglyceridemia